PDF (13 MB) - Jurnalul de Chirurgie

More documents

Recommendations

Info

Articole de sinteză Jurnalul de Chirurgie, Iaşi, 2011, Vol. 7, Nr. 1 [ISSN 1584 – 9341] 42. Liu TT, Fang Y, Xiong H, Chen TY, Ni ZP, Luo JF, Zhao NQ, Shen XZ. A case-control study of the relationship between hepatitis B virus DNA level and risk of hepatocellular carcinoma in Qidong, China. World J Gastroenterol. 2008; 14(19): 3059–3063. 43. Yang HI, Lu SN, Liaw YF, You SL, Sun CA, Wang LY, Hsiao CK, Chen PJ, Chen DS, Chen CJ. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002; 347(3): 168–174. 44. Chan HL, Tse CH, Mo F, Koh J, Wong VW, Wong GL, Lam Chan S, Yeo W, Sung JJ, Mok TS. High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma. J Clin Oncol. 2008; 26(2): 177–182. 45. Chu CJ, Hussain M, Lok AS. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology. 2002; 36(6): 1408–1415. 46. Yu MW, Yeh SH, Chen PJ, Liaw YF, Lin CL, Liu CJ, Shih WL, Kao JI, Chen DS, Chen CJ. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men. J Natl Cancer Inst. 2005; 97(4): 265–272. 47. Tsai FC, Liu CJ, Chen CL, Chen PJ, Lai MY, Kao JH, Chen DS. Lower serum viral loads in young patients with hepatitis-B-virus-related hepatocellular carcinoma. J Viral Hepat. 2007; 14(3): 153–160. 48. Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, Rossau R. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol. 2000; 81(Pt 1): 67–74. 49. Arauz-Ruiz P, Norder H, Robertson BH, Magnius LO. Genotype H: a new Amerindian genotype of hepatitis B virus revealed in Central America. J Gen Virol. 2002; 83(Pt 8): 2059–2073. 50. Kramvis A, Kew M, François G. Hepatitis B virus genotypes. Vaccine. 2005; 23(19): 2409– 2423. 51. Bowyer SM, van Staden L, Kew MC, Sim JG. A unique segment of the hepatitis B virus group A genotype identified in isolates from South Africa. J Gen Virol. 1997; 78(Pt 7): 1719–1729. 52. Kramvis A, Kew MC. Relationship of genotypes of hepatitis B virus to mutations, disease progression and response to antiviral therapy. J Viral Hepat. 2005; 12(5): 456–464. 53. Chan HL, Wong ML, Hui AY, Hung LC, Chan FK, Sung JJ. Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigenpositive patients. J Clin Microbiol. 2003; 41(3): 1277–1279. 54. Tsubota A, Arase Y, Ren F, Tanaka H, Ikeda K, Kumada H. Genotype may correlate with liver carcinogenesis and tumor characteristics in cirrhotic patients infected with hepatitis B virus subtype adw. J Med Virol. 2001; 65(2): 257–265. 55. Thakur V, Guptan RC, Kazim SN, Malhotra V, Sarin SK. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol. 2002; 17(2): 165–170. 56. Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992- 2001. Arch Intern Med. 2004; 164(21): 2349–2354. 57. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006; 44(1 suppl): S6–S9. 58. Bräu N, Fox RK, Xiao P, Marks K, Naqvi Z, Taylor LE, et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol. 2007; 47(4): 527–537. 59. Rosenthal E, Poirée M, Pradier C, Perronne C, Salmon-Ceron D, Geffray L, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS. 2003; 17(12): 1803–1809. 60. Clifford GM, Rickenbach M, Polesel J, Dal Maso L, Steffen I, Ledergerber B, et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS. 2008; 22(16): 2135–2141. 61. Thio CL, Seaberg EC, Skolasky R, Phair J, Visscher B, Munoz A, Thomas DL. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002; 360(9349): 1921–1926. 62. Elmberg M, Hultcrantz R, Ebrahim F, Olsson S, Lindgren S, Lööf L et al. Increased mortality risk in patients with phenotypic hereditary hemochromatosis but not in their first-degree relatives. Gastroenterology. 2009; 137(4): 1301-1309. 63. Coşciug G. Cancerul hepatic primar şi ciroza. Chişinău: Ed. ”Elan Poligraf”; 2009. p. 31-60. 19
Articole de sinteză Jurnalul de Chirurgie, Iaşi, 2011, Vol. 7, Nr. 1 [ISSN 1584 – 9341] 64. Asare GA, Mossanda KS, Kew MC, Paterson AC, Kahler-Venter CP, Siziba K. Hepatocellular carcinoma caused by iron overload: a possible mechanism of direct hepatocarcinogenicity. Toxicology. 2006; 219(1-3): 41–52. 65. El-Serag HB, Talwalkar J, Kim WR. Efficacy, effectiveness, and comparative effectiveness in liver disease. Hepatology. 2010; 52(2): 403-407. 66. Larsson SC, Wolk A. Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies. Br J Cancer. 2007; 97(7): 1005-1008. 67. Munaka M, Kohshi K, Kawamoto T, Takasawa S, Nagata N, Itoh H et al. Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2003; 129(6): 355-360. 68. Gallus S, Bertuzzi M, Tavani A, Bosetti C, Negri E, La Vecchia C et al. Does coffee protect against hepatocellular carcinoma? Br J Cancer. 2002; 87(9): 956–959. 69. Abdel-Wahab M, Mostafa M, Sabry M et al. Aflatoxins as a risk factor for hepatocellular carcinoma in Egypt, Mansoura Gastroenterology Center study. Hepatogastroenterology. 2008; 55(86-87): 1754–1759. 70. Bressac B, Kew M, Wands J et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature. 1991; 350(6317): 429–431. 71. Târcoveanu E, Moldovanu R. Tumorile maligne primare ale ficatului În Târcoveanu E, editor. Patologie chirurgicală hepatică tumori hepatice, Iaşi: Ed. Universitară „Gr. T. Popa”; 2007. p. 107-120. 72. Uto H, Kanmura S, Takami Y, Tsubouchi H. Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers. Proteome Sci. 2010; 8: 70. 73. Ishii M, Gama H, Chida N, Ueno Y, Shinzawa H, Takagi T, Toyota T, Takahashi T, Kasukawa R. Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. Am J Gastroenterol. 2000; 95(4): 1036–1040. 74. Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Takasaki K, Takenami K, Yamamoto M, Nakano M. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma. Cancer. 2000; 88(3): 544–549. 75. Marrero JA, Su GL, Wei W, Emick D, Conjeevaram HS, Fontana RJ, Lok AS. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients. Hepatology. 2003; 37(5): 1114–1121. 76. Ikoma J, Kaito M, Ishihara T, Nakagawa N, Kamei A, Fujita N, Iwasa M, Tamaki S, Watanabe S, Adachi Y. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum desgamma-carboxy prothrombin: a prospective study. Hepatogastroenterology. 2002; 49(43): 235– 238. 77. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Yamaguchi A, Isogai M, Kaneoka Y, Washizu J. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol. 2006; 4(1): 111– 117. 78. Nakamura S, Nouso K, Sakaguchi K, Ito YM, Ohashi Y, Kobayashi Y, Toshikuni N, Tanaka H, Miyake Y, Matsumoto E, Shiratori Y. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size. Am J Gastroenterol. 2006; 101(9): 2038–2043. 79. Espina V, Edmiston KH, Heiby M, Pierobon M, Sciro M, Merritt B, Banks S, Deng J, VanMeter AJ, Geho DH, Pastore L, Sennesh J, Petricoin EF, Liotta LA. A portrait of tissue phosphoprotein stability in the clinical tissue procurement process. Mol Cell Proteomics. 2008; 7(10): 1998– 2018. 80. Kriegsheim A, Preisinger C, Kolch W. Mapping of signaling pathways by functional interaction proteomics. Methods Mol Biol. 2008; 484: 177–192. 81. Carr BI, Pancoska P, Branch RA. Low alpha-fetoprotein hepatocellular carcinoma. J Gastroenterol Hepatol. 2010; 25(9): 1543-1549 82. Plathow C, Weber WA. Tumor cell metabolism imaging. J Nucl Med. 2008; 49(Suppl 2): 43S- 63S. 83. Frangioni JV. New technologies for human cancer imaging. J Clin Oncol. 2008; 26(24): 4012- 4021. 20
Page 2 and 3: Jurnalul de chirurgie îşi propune
Page 4 and 5: Cuprins Jurnalul de Chirurgie, Iaş
Page 6 and 7: Cuprins Jurnalul de Chirurgie, Iaş
Page 8 and 9: Editorial Jurnalul de Chirurgie, Ia
Page 14 and 15: Articole de sinteză Jurnalul de Ch
Page 34 and 35: Articole originale Jurnalul de Chir
Page 76 and 77:
Articole originale Jurnalul de Chir
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Cazuri clinice Jurnalul de Chirurgi
Page 88 and 89:
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Anatomie şi tehnici chirurgicale J
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Articole Multimedia Jurnalul de Chi
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Istorie Jurnalul de Chirurgie, Iaş
Page 138 and 139:
Page 140 and 141:
Page 142:
Recenzii Jurnalul de Chirurgie, Ia
show all

PDF (13 MB) - Jurnalul de Chirurgie

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?